Solving Purification for Advanced Therapies
ChromaGenix delivers GMP-ready affinity chromatography technologies to overcome common bottlenecks in downstream processing of viral vector, nucleic acid and antibody-based therapeutics.
Our tunable synthetic ligand platform is creating molecule-specific, unique solutions for more robust, scalable and cost-efficient manufacturing.
Purpose-designed for complex modalities
Overcoming Process Constraints
ChromaGenix technologies are developed to overcome the constraints that actually limit your downstream performance: recovery, impurity burden, elution conditions, cleaning compatibility and workflow fit. This allows us to open new routes to more robust, scalable and cost-efficient manufacturing.
A Tunable Synthetic Ligand Platform
Synthetic affinity ligands are well-established in commercial manufacturing. Our difference is the approach. Sequence, binding chemistry, ligand density and elution behavior are tuned from the ground up around each target and its impurity profile, then paired with the optimal base matrix.
US-based GMP Manufacturing
Development, scale-up and supply from US-based GMP and R&D facilities. We deliver the documentation, regulatory quality, batch-to-batch reproducibility and supply continuity that biomanufacturing teams require for commercial downstream processing.
Our focus areas
Universal binding. Mild elution pH. Higher functional recovery.
A purpose-designed affinity chromatography resin to overcome downstream processing bottlenecks in adeno-associated virus purification.
Move beyond non-selective impurity clearance.
Introducing our targeted HCP removal approach for viral vector processes. Improve downstream robustness without compromising yield.
ChromaGenix experts identify your key impurity bottlenecks and define the requirements for more effective impurity clearance.
Control complex impurity profiles without compromising recovery, product quality or process robustness.
ChromaGenix goes beyond bulk impurity reduction by targeting persistent and high-risk HCP subsets while preserving product recovery and ease of fit into established downstream workflows.
Our experts identify your key impurity bottlenecks and define the requirements for more effective impurity clearance.
Preserve functional vector while simplifying purification.
Our pseudotype-aware affinity approach is being developed to improve lentiviral vector recovery, impurity clearance and process consistency while reducing the need for repeated purification redevelopment across evolving LVV pipelines.
NAVIGATE is currently open to LVV process teams globally, providing early access to emerging technology, expertise and insight to shape the next-generation of LVV purification media.
Resolve dsRNA at the affinity capture step | reduce downstream polishing burden.
Double-stranded RNA is one of the most consequential impurities that can persist through conventional Oligo-dT capture. This introduces downstream burden, added polishing complexity, and immunogenicity risk.
ChromaGenix technology separates dsRNA and mRNA as distinct chromatographic species at the capture step, reducing dsRNA to near-LOQ levels across multiple mRNA constructs in development testing.
Forward-thinking ligand technology.
Many affinity workflows still rely on biologically derived ligands that were not developed for the diverse landscape of molecules driving the next generation of medicines.
ChromaGenix solutions are purpose-designed for the complex processing demands of today’s viral vector, mRNA and recombinant protein processes.
Why wait for better purification tools when you can shape them?
For demanding purification challenges, NAVIGATE connects you with process expertise, new purification technologies, process insights and collabration opportunities to shape and implement a GMP-ready solution.
- Early access to ChromaGenix technologies
- Scientist to scientist collaboration with R&D and Applications team
- Guide product specifications to overcome DSP bottlenecks
- Early access to insight, data and application notes
- Peer roundtables with senior manufacturing professionals across four modalities
Professor Stefano Menegatti
NC STATE UNIVERSITY | CHROMAGENIX
Dr. Menegatti is a Professor and Faculty Scholar in the Department of Chemical and Biomolecular Engineering at NC State University and co-founder of the North Carolina Viral Vector Initiative in Research and Learning (NC-VVIRAL).
Dr. Menegatti’s main interests are in purification processes and analytical technologies dedicated to biological therapeutics. His group introduced the paradigm of “flow-through affinity chromatography” and a number of affinity ligands for the purification of proteins, viral vectors, and cells, and has authored over 120 papers and 20 patents.
NAVIGATE tracks
NAVIGATE is currently focused on four specific modalities. Select your modality to see the specific challenges, questions, and data we bring to that conversation.
Get in touch with us today.
Whether you’re exploring purification solutions, have a technical question, or want to learn more about our technologies, we’re here to help. Complete the form and a member of our team will be in touch shortly.